Prognostic role of lemur tyrosine kinase-3 germline polymorphisms in adjuvant gastric cancer in Japan and the United States

Molecular Cancer Therapeutics

Volumn 12, Issue 10, 2013, Pages 2261-2272

  Wakatsuki, Takeru ^a,e   LaBonte, Melissa J ^b   Bohanes, Pierre O ^a   Zhang, Wu ^a   Yang, Dongyun ^a   Azuma, Mizutomo ^c   Barzi, Afsaneh ^a   Ning, Yan ^a   Loupakis, Fotios ^a   Saadat, Siamak ^a   Volz, Nico ^a   Stintzing, Sebastian ^a   El Khoueiry, Rita ^a   Koizumi, Wasaburo ^c   Watanabe, Masahiko ^d   Shah, Manish ^f   Stebbing, Justin ^g   Giamas, Georgios ^g   Lenz, Heinz Josef ^a  

^a UNIVERSITY OF SOUTHERN CALIFORNIA   (United States)

^b AZUSA PACIFIC UNIVERSITY   (United States)

^c Hepatology and Nutrition   (United States)

^d KITASATO UNIVERSITY HOSPITAL   (Japan)

^e Fukushima Red Cross Hospital   (Japan)

^f Fukushima Red Cross Hospital ^*  (United States)

^g IMPERIAL COLLEGE LONDON   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ESTROGEN; LEMUR TYROSINE KINASE 3; PROTEIN TYROSINE KINASE; UNCLASSIFIED DRUG;

AGED; ARTICLE; CANCER PATIENT; CANCER PROGNOSIS; CANCER RECURRENCE; CANCER SURVIVAL; COHORT ANALYSIS; CONTROLLED STUDY; DISEASE FREE SURVIVAL; DNA EXTRACTION; DNA SEQUENCE; FEMALE; GENDER; GENETIC POLYMORPHISM; GENOTYPE; GERM LINE; HUMAN; HUMAN TISSUE; JAPAN; MAJOR CLINICAL STUDY; MALE; OVERALL SURVIVAL; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; STOMACH ADENOCARCINOMA; UNITED STATES;

ADULT; AGED; DISEASE-FREE SURVIVAL; ESTROGEN RECEPTOR ALPHA; FEMALE; GENETIC ASSOCIATION STUDIES; HUMANS; JAPAN; MALE; MEMBRANE PROTEINS; MIDDLE AGED; PROGNOSIS; PROTEIN-SERINE-THREONINE KINASES; STOMACH NEOPLASMS; TUMOR MARKERS, BIOLOGICAL; UNITED STATES;

EID: 84885582669     PISSN: 15357163     EISSN: 15388514     Source Type: Journal    
DOI: 10.1158/1535-7163.MCT-12-1134     Document Type: Article

References (56)

1. Kamangar F, Dores GM, Anderson WF. Patterns of cancer incidence, mortality, and prevalence across five continents: defining priorities to reduce cancer disparities in different geographic regions of the world. J Clin Oncol 2006;24: 2137-50.
2. Center for Cancer Control and Information Services, National Cancer Center Japan. [cited 2012; accessed 2012 May 23]. Available from: http://ganjoho.jp/professional/statistics/statistics.html#08.
3. The American Cancer Society. What are the key statistics about stomach cancer? [cited 2012; accessed 2012 May 23]. Available from: http://www.cancer. org/cancer/stomachcancer/detailedguide/stomach- cancer-key-statistics.
4. Yao JC, Schnirer II, Reddy S, Chiang S, Najam A, Yu C, et al. Effects of sex and racial/ethnic group on the pattern of gastric cancer localization. Gastric Cancer 2002;5: 208-12.
5. Yao JC, Tseng JF, Worah S, Hess KR, Mansfield PF, Crane CH, et al. Clinicopathologic behavior of gastric adenocarcinoma in Hispanic patients: analysis of a single institution's experience over 15 years. J Clin Oncol 2005;23: 3094-103.
6. Crew KD, Neugut AI. Epidemiology of upper gastrointestinal malignancies. Semin Oncol 2004;31: 450-64.
7. Shah MA, Khanin R, Tang L, Janjigian YY, Klimstra DS, Gerdes H, et al. Molecular classification of gastric cancer: anew paradigm. Clin Cancer Res 2011;17: 2693-701.
8. Tanner M, Hollmen M, Junttila TT, Kapanen AI, Tommola S, Soini Y, et al. Amplification of HER-2 in gastric carcinoma: association with Topoisomerase IIalpha gene amplification, intestinal type, poor prognosis and sensitivity to trastuzumab. Ann Oncol 2005;16: 273-8.
9. Gravalos C, Jimeno A. HER2 in gastric cancer: a new prognostic factor and a novel therapeutic target. Ann Oncol 2008;19: 1523-9.
10. Terashima M, Kitada K, Ochiai A, Ichikawa W, Kurahashi I, Sakuramoto S, et al. Impact of expression of human epidermal growth factor receptors EGFR and ERBB2 on survival in stage II/III gastric cancer. Clin Cancer Res 2012;18: 5992-6000.
11. Graziano F, Humar B, Guilford P. The role of the E-cadherin gene (CDH1) in diffuse gastric cancer susceptibility: from the laboratory to clinical practice. Ann Oncol 2003;14: 1705-13.
12. Nakajima M, Sawada H, Yamada Y, Watanabe A, Tatsumi M, Yamashita J, et al. The prognostic significance of amplification and overexpression of c-met and c-erb B-2 in human gastric carcinomas. Cancer 1999;85: 1894-902.
13. Macdonald JS, Smalley SR, Benedetti J, Hundahl SA, Estes NC, Stemmermann GN, et al. Chemoradiotherapy after surgery compared with surgery alone for adenocarcinoma of the stomach or gastroesophageal junction. N Engl J Med 2001;345: 725-30.
14. Cunningham D, Allum WH, Stenning SP, Thompson JN, Van de Velde CJ, Nicolson M, et al. Perioperative chemotherapy versus surgery alone for resectable gastroesophageal cancer. N Engl J Med 2006; 355: 11-20.
15. Sakuramoto S, Sasako M, Yamaguchi T, Kinoshita T, Fujii M, Nashimoto A, et al. Adjuvant chemotherapy for gastric cancer with S-1, an oral fluoropyrimidine. N Engl J Med 2007;357: 1810-20.
16. Hendifar A, Yang D, Lenz F, Lurje G, Pohl A, Lenz C, et al. Gender disparities in metastatic colorectal cancer survival. Clin Cancer Res 2009;15: 6391-7.
17. Bohanes P, Yang D, Chhibar RS, Labonte MJ, Winder T, Ning Y, et al. Influence of sex on the survival of patients with esophageal cancer. J Clin Oncol 2012;30: 2265-72.
18. Rossouw JE, Anderson GL, Prentice RL, LaCroix AZ, Kooperberg C, Stefanick ML, et al. Risks and benefits of estrogen plus progestin in healthy postmenopausal women: principal results From the Women's Health Initiative randomized controlled trial. JAMA 2002; 288: 321-33.
19. Camargo MC, Goto Y, Zabaleta J, Morgan DR, Correa P, Rabkin CS. Sex hormones, hormonal interventions, and gastric cancer risk: a meta-analysis. Cancer Epidemiol Biomarkers Prev 2012;21: 20-38.
20. Rutqvist LE, Johansson H, Signomklao T, Johansson U, Fornander T, Wilking N. Adjuvant tamoxifen therapy for early stage breast cancer and second primary malignancies. Stockholm Breast Cancer Study Group. J Natl Cancer Inst 1995;87: 645-51.
21. Chandanos E, Lindblad M, Jia C, Rubio CA, Ye W, Lagergren J. Tamoxifen exposure and risk of oesophageal and gastric adenocarcinoma: a population-based cohort study of breast cancer patients in Sweden. Br J Cancer 2006;95: 118-22.
22. Sipponen P, Correa P. Delayed rise in incidence of gastric cancer in females results in unique sex ratio (M/F) pattern: etiologic hypothesis. Gastric Cancer 2002;5: 213-9.
23. Derakhshan MH, Liptrot S, Paul J, Brown IL, Morrison D, McColl KE. Oesophageal and gastric intestinal-type adenocarcinomas show the same male predominance due to a 17 year delayed development in females. Gut 2009;58: 16-23.
24. Brandenberger AW, Tee MK, Lee JY, Chao V, Jaffe RB. Tissue distribution of estrogen receptors alpha (ER-alpha) and beta (ER-beta) mRNA in the midgestational human fetus. J Clin Endocrinol Metab 1997;82: 3509-12.
25. Gustafsson JA. Estrogen receptor beta-a new dimension in estrogen mechanism of action. J Endocrinol 1999;163: 379-83.
26. Matsuyama S, Ohkura Y, Eguchi H, Kobayashi Y, Akagi K, Uchida K, et al. Estrogen receptor beta is expressed in human stomach adenocarcinoma. J Cancer Res Clin Oncol 2002;128: 319-24.
27. Chandanos E, Rubio CA, Lindblad M, Jia C, Tsolakis AV, Warner M, et al. Endogenous estrogen exposure in relation to distribution of histological type and estrogen receptors in gastric adenocarcinoma. Gastric Cancer 2008;11: 168-74.
28. Wang M, Pan JY, Song GR, Chen HB, An LJ, QuSX. Altered expression of estrogen receptor alpha and beta in advanced gastric adenocarcinoma: correlation with prothymosin alpha and clinicopathological parameters. Eur J Surg Oncol 2007;33: 195-201.
29. Xu CY, Guo JL, Jiang ZN, Xie SD, Shen JG, Shen JY, et al. Prognostic role of estrogen receptor alpha and estrogen receptor beta in gastric cancer. Ann Surg Oncol 2010;17: 2503-9.
30. Ryu WS, KimJH, Jang YJ, Park SS, UmJW, Park SH, et al. Expression of estrogen receptors in gastric cancer and their clinical significance. J Surg Oncol 2012;106: 456-61.
31. Edvardsson K, Strom A, Jonsson P, Gustafsson JA, Williams C. Estrogen receptor beta induces antiinflammatory and antitumorigenic networks in colon cancer cells. Mol Endocrinol 2011;25: 969-79.
32. Lindberg K, Strom A, Lock JG, Gustafsson JA, Haldosen LA, Helguero LA. Expression of estrogen receptor beta increases integrin alpha1 and integrin beta1 levels and enhances adhesion of breast cancer cells. J Cell Physiol 2010;222: 156-67.
33. Liu MM, Albanese C, Anderson CM, Hilty K, Webb P, Uht RM, et al. Opposing action of estrogen receptors alpha and beta on cyclin D1 gene expression. J Biol Chem 2002;277: 24353-60.
34. Helguero LA, Faulds MH, Gustafsson JA, Haldosen LA. Estrogen receptors alfa (ERalpha) and beta (ERbeta) differentially regulate proliferation and apoptosis of the normal murine mammary epithelial cell line HC11. Oncogene 2005;24: 6605-16.
35. Giamas G, Filipovic A, Jacob J, Messier W, Zhang H, Yang D, et al. Kinome screening for regulators of the estrogen receptor identifies LMTK3 as a new therapeutic target in breast cancer. Nat Med 2011; 17: 715-9.
36. Stebbing J, Filipovic A, Lit LC, Blighe K, Grothey A, Xu Y, et al. LMTK3is implicated in endocrine resistance via multiple signaling pathways. Oncogene 2013;32: 3371-80.
37. Stebbing J, Filipovic A, Ellis IO, Green AR, D'Silva TR, Lenz HJ, et al. LMTK3 expression in breast cancer: association with tumor phenotype and clinical outcome. Breast Cancer Res Treat 2012;132: 537-44.
38. Loupakis F, Zhang W, Gerger A, Yang D, Bohanes P, Labonte MJ, et al. LMTK3 polymorphism in patients with metastatic colon cancer [abstract]. J Clin Oncol 30, 2012 (suppl 4; abstr 471).
39. Zhang W, Gerger A, Labonte MJ, Yang D, Bohanes P, Ning Y, et al. Association of gender-related tumor recurrence with a polymorphic variant of LMTK3 in stage II and III colon cancer [abstract]. J Clin Oncol 30, 2012 (suppl 4; abstr 454).
40. McShane LM, Altman DG, Sauerbrei W, Taube SE, Gion M, Clark GM, et al. REporting recommendations for tumour MARKer prognostic studies (REMARK). Br J Cancer 2005;93: 387-91.
41. Rose DP, Vona-Davis L. Interaction between menopausal status and obesity in affecting breast cancer risk. Maturitas 2010;66: 33-8.
42. Wu AH, Stanczyk FZ, Seow A, Lee HP, Yu MC. Soy intake and other lifestyle determinants of serum estrogen levels among postmenopausal Chinese women in Singapore. Cancer Epidemiol Biomarkers Prev 2002;11: 844-51.
43. Kim C, Golden SH, Mather KJ, Laughlin GA, Kong S, Nan B, et al. Racial/ethnic differences in sex hormone levels among postmenopausal women in the diabetes prevention program. J Clin Endocrinol Metab 2012;97: 4051-60.
44. Yasui T, Uemura H, Irahara M, Arai M, Kojimahara N, Okabe R, et al. Associations of endogenous sex hormones and sex hormone-binding globulin with lipid profiles in aged Japanese men and women. Clin Chim Acta 2008;398: 43-7.
45. Vaidya D, Dobs A, Gapstur SM, Golden SH, Cushman M, Liu K, et al. Association of baseline sex hormone levels with baseline and longitudinal changes in waist-to-hip ratio: Multi-Ethnic Study of Atherosclerosis. Int J Obes 2012;36: 1578-84.
46. Weitsman GE, Weebadda W, Ung K, Murphy LC. Reactive oxygen species induce phosphorylation of serine 118 and 167 on estrogen receptor alpha. Breast Cancer Res Treat 2009;118: 269-79.
47. Lam HM, Suresh Babu CV, Wang J, Yuan Y, Lam YW, Ho SM, et al. Phosphorylation of human estrogen receptor-beta at serine 105 inhibits breast cancer cell migration and invasion. Mol Cell Endocrinol 2012;358: 27-35.
48. Hamilton-Burke W, Coleman L, Cummings M, Green CA, Holliday DL, Horgan K, et al. Phosphorylation of estrogen receptor beta at serine 105 is associated with good prognosis in breast cancer. Am J Pathol 2010;177: 1079-86.
49. Lee PH, Shatkay H. F-SNP: computationally predicted functional SNPs for disease association studies. Nucleic Acids Res 2008;36: D820-4.
50. Pagani F, Baralle FE. Genomic variants in exons and introns: identifying the splicing spoilers. Nat Rev Genet 2004;5: 389-96.
51. Saeki T, Sano M, Komoike Y, Sonoo H, Honjyo H, Ochiai K, et al. No increase of breast cancer incidence in Japanese women who received hormone replacement therapy: overview of a case-control study of breast cancer risk in Japan. Int J Clin Oncol 2008; 13: 8-11.
52. Breast cancer and hormonal contraceptives: collaborative reanalysis of individual data on 53 297 women with breast cancer and 100 239 women without breast cancer from 54 epidemiological studies. Collaborative Group on Hormonal Factors in Breast Cancer. Lancet 1996;347: 1713-27.
53. Matsuyama Y, Tominaga T, Nomura Y, Koyama H, Kimura M, Sano M, et al. Second cancers after adjuvant tamoxifen therapy for breast cancer in Japan. Ann Oncol 2000;11: 1537-43.
54. Moon YW, Park S, Sohn JH, Kang DR, Koo JS, Park HS, et al. Clinical significance of progesterone receptor and HER2 status in estrogen receptor-positive, operable breast cancer with adjuvant tamoxifen. J Cancer Res Clin Oncol 2011;137: 1123-30.
55. De Laurentiis M, Arpino G, Massarelli E, Ruggiero A, Carlomagno C, Ciardiello F, et al. A meta-analysis on the interaction between HER-2 expression and response to endocrine treatment in advanced breast cancer. Clin Cancer Res 2005;11: 4741-8.
56. Yang Z, Barnes CJ, Kumar R. Human epidermal growth factor receptor 2 status modulates subcellular localization of and interaction with estrogen receptor alpha in breast cancer cells. Clin Cancer Res 2004; 10: 3621-8.